Is an original anti-epileptic drug from BIOCODEX’s research program. It is not related to any other known anticonvulsants.

On January 8th 2014, the conditional approval originally given to DIACOMIT® was switched to full European Marketing Authorisation for use in conjunction with valproate and clobazam as adjunctive therapy of refractory generalized tonic-clonic seizures in patients with Severe Myoclonic Epilepsy in Infancy (SMEI, Dravet's syndrome) whose seizures are not adequately controlled with clobazam and valproate.

DIACOMIT ® is available both in hard capsules and powder for oral suspension in sachets in 250mg and 500mg.

DIACOMIT® should only be administered under the supervision of a paediatrician / paediatric neurologist experienced in the diagnosis and management of epilepsy in infants and children.

 

 For any further information, please do not hesitate to contact us: